mProX™ Human CCR9 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CCR9, or C-C chemokine receptor type 9, is a protein that has been the subject of extensive research due to its involvement in various physiological and pathological processes. One of the most notable findings is its expression in over 70% of cases of T-ALL, a type of acute lymphoblastic leukemia. Specifically, chimeric antigen receptor (CAR)-T cells targeting CCR9 have shown significant anti-leukemic activity both in vitro and in vivo, suggesting potential therapeutic applications for relapsed or refractory T-ALL cases. Furthermore, CCR9 plays a role in the differentiation and function of CD4 T cells in the gut, impacting tissue homeostasis and immune responses. Another study highlighted the role of CCR9 in the migration of plasmacytoid dendritic cells (pDCs) to the liver, suggesting potential therapeutic applications in acute liver disease. The CCR9 axis has also been implicated in the immunopathology of primary Sjögren's Syndrome, a chronic autoimmune disorder. Overall, the diverse roles of CCR9 in immune responses, cancer, and other diseases make it a promising target for therapeutic interventions and further research.